LitCovid-sample-Enju  

PMC:7205724 / 5679-6063 JSONTXT 16 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T933 3-4 NN denotes S
T934 5-12 NN denotes protein
T935 13-16 CC denotes and
T936 17-28 JJ denotes proteolytic
T937 29-36 NN denotes process
T938 37-39 IN denotes so
T939 40-44 IN denotes that
T940 45-49 PRP denotes they
T941 50-60 VBP denotes facilitate
T942 61-64 DT denotes the
T943 65-70 NN denotes virus
T944 71-75 NN denotes cell
T945 76-81 NN denotes entry
T946 83-91 RB denotes Moreover
T947 91-92 -COMMA- denotes ,
T948 93-94 DT denotes a
T949 95-100 NN denotes virus
T950 101-105 IN denotes with
T951 106-109 DT denotes the
T952 110-122 VBN denotes glycosylated
T953 123-135 NN denotes glycoprotein
T954 136-141 VBZ denotes gains
T955 142-144 DT denotes an
T956 145-150 JJ denotes extra
T957 151-158 NN denotes feature
T958 159-162 IN denotes for
T959 163-165 DT denotes an
T960 166-172 NN denotes escape
T961 173-177 IN denotes from
T962 178-181 DT denotes the
T963 182-188 JJ denotes immune
T964 189-198 NNS denotes responses
T965 200-209 RB denotes Therefore
T966 209-210 -COMMA- denotes ,
T967 211-218 NNS denotes glycans
T968 219-222 VBP denotes are
T969 223-224 DT denotes a
T970 225-229 JJ denotes good
T971 230-236 NN denotes target
T972 237-240 IN denotes for
T973 241-248 NN denotes vaccine
T974 249-255 NN denotes design
T975 257-260 CD denotes Two
T976 261-265 JJ denotes main
T977 266-271 NNS denotes types
T978 272-274 IN denotes of
T979 275-282 NNS denotes glycans
T980 283-286 VBP denotes are
T981 287-295 VBN denotes N-linked
T982 296-299 CC denotes and
T983 300-308 JJ denotes O-linked
T984 309-316 NNS denotes glycans
T985 318-322 DT denotes Both
T986 323-326 VBP denotes are
T987 327-335 VBN denotes released
T988 336-340 IN denotes from
T989 341-354 NNS denotes glycoproteins
T990 356-363 IN denotes Whereas
T991 364-371 NNS denotes enzymes
T992 372-379 VBP denotes fulfill
T993 380-383 DT denotes the
R929 T934 T933 arg1Of protein,S
R930 T934 T935 arg1Of protein,and
R931 T937 T935 arg2Of process,and
R932 T937 T936 arg1Of process,proteolytic
R934 T941 T938 arg2Of facilitate,so
R935 T938 T939 arg1Of so,that
R936 T940 T941 arg1Of they,facilitate
R937 T945 T941 arg2Of entry,facilitate
R938 T945 T942 arg1Of entry,the
R939 T945 T943 arg1Of entry,virus
R940 T945 T944 arg1Of entry,cell
R941 T954 T946 arg1Of gains,Moreover
R942 T954 T947 arg1Of gains,","
R943 T949 T948 arg1Of virus,a
R944 T949 T950 arg1Of virus,with
R945 T953 T950 arg2Of glycoprotein,with
R946 T953 T951 arg1Of glycoprotein,the
R947 T953 T952 arg2Of glycoprotein,glycosylated
R948 T949 T954 arg1Of virus,gains
R949 T957 T954 arg2Of feature,gains
R950 T957 T955 arg1Of feature,an
R951 T957 T956 arg1Of feature,extra
R952 T957 T958 arg1Of feature,for
R953 T960 T958 arg2Of escape,for
R954 T960 T959 arg1Of escape,an
R955 T960 T961 arg1Of escape,from
R956 T964 T961 arg2Of responses,from
R957 T964 T962 arg1Of responses,the
R958 T964 T963 arg1Of responses,immune
R959 T968 T965 arg1Of are,Therefore
R960 T968 T966 arg1Of are,","
R961 T967 T968 arg1Of glycans,are
R962 T971 T968 arg2Of target,are
R963 T971 T969 arg1Of target,a
R964 T971 T970 arg1Of target,good
R965 T971 T972 arg1Of target,for
R966 T974 T972 arg2Of design,for
R967 T974 T973 arg1Of design,vaccine
R968 T977 T975 arg1Of types,Two
R969 T977 T976 arg1Of types,main
R970 T977 T978 arg1Of types,of
R971 T979 T978 arg2Of glycans,of
R972 T977 T980 arg1Of types,are
R973 T981 T980 arg2Of N-linked,are
R974 T977 T981 arg2Of types,N-linked
R975 T984 T981 arg3Of glycans,N-linked
R976 T984 T982 arg1Of glycans,and
R977 T984 T983 arg1Of glycans,O-linked
R978 T985 T986 arg1Of Both,are
R979 T987 T986 arg2Of released,are
R980 T985 T987 arg2Of Both,released
R981 T987 T988 arg1Of released,from
R982 T989 T988 arg2Of glycoproteins,from
R984 T992 T990 arg2Of fulfill,Whereas
R985 T991 T992 arg1Of enzymes,fulfill